Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma

1 Nov 1998

Abstract excerpt

Diffuse large B-cell lymphoma (DLCL) is characterized by a marked degree of morphologic and clinical heterogeneity. We studied 156 patients with de novo DLCL for rearrangements of the BCL2, BCL6, and MYC oncogenes by Southern blot analysis and BCL2 protein expression. We related these data to the primary site of presentation, disease stage, and other clinical risk factors. Structural alterations of BCL2, BCL6,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 9787151
DOI: 10.1182/blood.v92.9.3152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell LymphomaPMID 9787151Read ↗

Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Rearrangements of Bcl-1, Bcl-2, Bcl-6, and C-Myc in Diffuse Large B-Cell LymphomasSemantic proximity Read ↗

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabSemantic proximity Read ↗

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapySemantic proximity Read ↗

<i>MYC</i> translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphomaSemantic proximity Read ↗

The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphomaSemantic proximity Read ↗

Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.Semantic proximity Read ↗

MYC alterations in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.Semantic proximity Read ↗

The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.